Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort [0.03%]
ESME-MBC队列中HR阳性/HER2阴性转移性乳腺癌患者对CDK4/6抑制剂治疗后疾病进展后的实际治疗模式和疗效分析
R Varnier,D Pérol,W Jacot et al.
R Varnier et al.
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved the prognosis of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), but their...
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development [0.03%]
从毒性评估到适应性安全保障:实施全面快速通道安全评价以促进抗癌药物研发
S Champiat,K Ouali,A Laparra et al.
S Champiat et al.
Background: The conventional drug development pathway in oncology, spanning 10-15 years, has long been slow, costly, and complex, often marked by late-stage failures due to efficacy or safety concerns. ...
Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing [0.03%]
通过全外显子RNA测序评估间充质肿瘤中的靶向NTRK1/2/3融合基因状况
H Vanacker,M Brahmi,D Pissaloux et al.
H Vanacker et al.
Background: Neurotrophic receptor tyrosine kinase (NTRK) 1/2/3 fusions, though rare, are highly sought in cancer diagnostics due to tyrosine kinase inhibitors' histology-agnostic approval based on significant efficacy acr...
Clinical characteristics and prognosis of pulmonary lymphoepithelioma-like carcinoma: a multicenter cohort study of 1106 cases [0.03%]
肺淋巴上皮样癌的临床特征及预后:一项1106例多中心队列研究
Z Hou,M Lan,Y-X Zhu et al.
Z Hou et al.
Background: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of squamous lung cancer with clinical features that have conflicting findings from different studies. Meanwhile, the survival time, pattern of ...
Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe [0.03%]
基于欧洲多家机构的真实世界数据探究NGS在软组织肉瘤诊断和治疗中的影响及启示
A Kyriazoglou,A Zając,C Valverde et al.
A Kyriazoglou et al.
Background: Sarcomas comprise a heterogeneous group of malignant tumors of mesenchymal origin where diagnosis plays a crucial role in tailoring disease management and treatment. In this context, there is a lack of data as...
A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors [0.03%]
一项关于AZD8186与多西他赛联合治疗PTEN基因或PIK3CB基因突变的晚期实体瘤患者的I期临床研究
A M Schram,N Takebe,A Chen et al.
A M Schram et al.
Background: Loss of PTEN activity is common in solid tumors and promotes cancer growth through activation of the PI3K pathway. PTEN-deficient tumors have increased dependence on PI3Kβ and are sensitive to PI3Kβ inhibiti...
Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer [0.03%]
DNA损伤修复改变对转移性结直肠癌真实世界治疗反应的影响
L Miotke,C Norton,Z Rubnitz et al.
L Miotke et al.
Background: Alterations in DNA damage repair (DDR) pathway genes can be exploited by cytotoxic chemotherapy regimens that induce DNA damage. Platinum chemotherapy has been shown to be particularly effective in DDR-mutated...
Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study [0.03%]
2015年至2024年利什曼病患者接受免疫检查点抑制剂治疗消化道癌症期间dMMR/MSI-H肿瘤发生率的回顾性分析:单中心前瞻性队列研究
A Pellat,C Loisel,J Metras et al.
A Pellat et al.
Background: Immune checkpoint inhibitors (ICIs) represent a paradigm shift and a therapeutic revolution in the management of mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), ...
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses [0.03%]
可切除NSCLC的免疫治疗:新辅助/围手术期免疫治疗联合手术 VS 手术联合辅助免疫治疗:系统评价和Meta分析及亚组分析
G Rossi,L Barcellini,M Tagliamento et al.
G Rossi et al.
Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperat...